2型糖尿病患者における薬剤NNC0662-0419の異なる投与量による血糖値低下効果を比較した研究

基本情報

NCT ID

NCT07415954

ステータス

募集前

試験のフェーズ

第2相

試験タイプ

介入

目標被験者数

270

治験依頼者名

Novo Nordisk A/S

概要

This study is being done to look at the effect and safety of different doses of NNC0662-0419 in people living with type 2 diabetes when compared to placebo or semaglutide. The purpose of this clinical study is to find out if NNC0662-0419 is effective and safe for treating people living with type 2 diabetes. Participants will get either NNC0662-0419, semaglutide or placebo. Which treatment participants get is decided by chance. NNC0662-0419 is a new medicine which cannot be prescribed by doctors but has previously been tested in humans. Semaglutide is an approved medication to treat type 2 diabetes.

対象疾患

介入

依頼者（Sponsor）

実施施設 (5)